StockData
Edesa Biotech, Inc. logo

Edesa Biotech, Inc. (EDSA) stock

EDSANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026Score 6/30
$1.96+0.07 (+3.70%)

Close on Nov 17, 2026Market cap $18.90MP/E –Yield –

Edesa Biotech r&d expenses

Research and development expenses are spending on new products and technology.

Edesa Biotech's R&D Expenses for the twelve months ending Jun 30, 2026 was $9.08M, up 256.3% year over year. For fiscal 2025 it was $3.67M, up 27.3% from the year before. Over ten years it grew 6.2% a year on average. The highest annual figure on record is $17.95M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$3.67M+27.3%
FY2024Sep 30, 2024$2.88M-39.9%
FY2023Sep 30, 2023$4.79M-64.0%
FY2022Sep 30, 2022$13.34M-25.7%
FY2021Sep 30, 2021$17.95M+439.0%
FY2020Sep 30, 2020$3.33M+59.5%
FY2018Sep 30, 2018$2.09M+5.8%
FY2017Sep 30, 2017$1.97M+14.1%
FY2016Sep 30, 2016$1.73M-29.7%
FY2014Aug 31, 2014$2.46M+21.8%
FY2013Aug 31, 2013$2.02M-23.4%
FY2012Aug 31, 2012$2.63M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$3.96M+321.5%
Q2 FY2026CQ1 2026Mar 31, 2026$2.77M+471.4%
Q1 FY2026CQ4 2025Dec 31, 2025$1.12M+10.3%
Q4 FY2025CQ3 2025Sep 30, 2025$1.23M+1079.9%
Q3 FY2025CQ2 2025Jun 30, 2025$939.07K+4.7%
Q2 FY2025CQ1 2025Mar 31, 2025$484.31K-58.8%
Q1 FY2025CQ4 2024Dec 31, 2024$1.02M+44.8%
Q4 FY2024CQ3 2024Sep 30, 2024$103.87K-89.1%
Q3 FY2024CQ2 2024Jun 30, 2024$897.31K-12.5%
Q2 FY2024CQ1 2024Mar 31, 2024$1.18M-19.3%
Q1 FY2024CQ4 2023Dec 31, 2023$704.46K-48.1%
Q4 FY2023CQ3 2023Sep 30, 2023$953.40K-46.9%
Q3 FY2023CQ2 2023Jun 30, 2023$1.03M-77.4%
Q2 FY2023CQ1 2023Mar 31, 2023$1.46M-52.1%
Q1 FY2023CQ4 2022Dec 31, 2022$1.36M-65.6%
Q4 FY2022CQ3 2022Sep 30, 2022$1.79M-56.5%
Q3 FY2022CQ2 2022Jun 30, 2022$4.55M+1.9%
Q2 FY2022CQ1 2022Mar 31, 2022$3.04M-61.8%
Q1 FY2022CQ4 2021Dec 31, 2021$3.95M+186.4%
Q4 FY2021CQ3 2021Sep 30, 2021$4.13M+257.5%
Q3 FY2021CQ2 2021Jun 30, 2021$4.46M+290.3%
Q2 FY2021CQ1 2021Mar 31, 2021$7.98M+1486.1%
Q1 FY2021CQ4 2020Dec 31, 2020$1.38M+161.3%
Q4 FY2020CQ3 2020Sep 30, 2020$1.15M+129.6%
Q3 FY2020CQ2 2020Jun 30, 2020$1.14M+924.0%
Q2 FY2020CQ1 2020Mar 31, 2020$502.81K+95.4%
Q1 FY2020CQ4 2019Dec 31, 2019$528.00K+6.2%
Q3 FY2019CQ2 2019Jun 30, 2019$502.93K+68.6%
Q2 FY2019CQ1 2019Mar 31, 2019$111.70K-77.4%
Q1 FY2019CQ4 2018Dec 31, 2018$257.39K-59.2%
Q4 FY2018CQ3 2018Sep 30, 2018$497.32K-23.1%
Q3 FY2018CQ2 2018Jun 30, 2018$298.22K-44.4%
Q2 FY2018CQ1 2018Mar 31, 2018$493.87K+49.9%
Q1 FY2018CQ4 2017Dec 31, 2017$631.03K+36.9%
Q4 FY2017CQ3 2017Sep 30, 2017$647.00K-2.2%
Q3 FY2017CQ2 2017Jun 30, 2017$536.17K–
Q2 FY2017CQ1 2017Mar 31, 2017$329.37K–
Q1 FY2017CQ4 2016Dec 31, 2016$460.87K–
Q4 FY2016CQ3 2016Sep 30, 2016$661.44K–

More Edesa Biotech figures

See a number that looks wrong?